The Neuroepidemiology Research Group
We are a multidisciplinary research group interested in different aspects of epidemiology of Multiple Sclerosis (MS). Our group consisted of epidemiologists, geneticists, neurologists, immunologists and mathematicians. The group addresses questions facing patients, physicians and researchers with an aim to forge understanding of mechanisms behind development of MS and its clinical course. We aim to foster cross-disciplinary collaborations between researchers, patients and clinicians through several national and international projects.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system affecting around one million people world-wide. The disease progression varies between patients but often causes different degrees of disability. In the MS group at CMM we aim to contribute to the urgently needed advancement of MS research by applying translational methods based on large patient cohorts. In this way hope to cast new light on the etiology of MS by seeking to understand the genetic components of the disease. We are also investigating a possible viral etiology of the disease using experimental systems. MS treatments have improved significantly over the last decade, but they are still only partially effective and/or hampered by side effects, leaving a great clinical need for intensified research on disease mechanisms and novel therapeutics.
Genetics of MS
What triggers MS?
What provokes progression?
What are the social and economic consequences of MS?
Listen to an inspirational lecture by our group leader
Listen to an inspirational lecture by our group leader, professor Jan Hillert. He is telling us about a new promising clinical research field.
Digging for gold in registries and biobanks
Katharina's research is driven by the contact with her patients, addressing relevant clinical knowledge gaps. Advocating female patients with MS she is interested in research directed at pregnancy, health and socioeconomic outcomes in mothers with MS, as well as their children. In line with this, she is currently involved in a study investigating the risk profile of rituximab in women with MS that have been exposed to rituximab around their pregnancy. The study looks at delivery complications, birth defects and adverse birth outcomes in patients´ children, as well as structured long-term outcomes.
Sahl Khalid Bedri
Virginija Danylaité Karrenbauer
Age Related Multiple Sclerosis Severity Score: Disability ranked by age.
Mult. Scler. 2017 Jan;():1352458517690618
Similar familial risk in multiple sclerosis subgroups.
Mult. Scler. 2017 Jan;():1352458516684214
Income in Multiple Sclerosis Patients with Different Disease Phenotypes.
PLoS ONE 2017 ;12(1):e0169460
Clinical course of multiple sclerosis: A nationwide cohort study.
Mult. Scler. 2016 Dec;():1352458516681197
Importance of early treatment initiation in the clinical course of multiple sclerosis.
Mult. Scler. 2017 Aug;23(9):1233-1240
The Swedish MS registry – clinical support tool and scientific resource.
Acta Neurol. Scand. 2015 ;132(199):11-9
Visiting address: Widerströmska Huset, Tomtebodavägen 18a, 5 Tr, 171 77 Stockholm, Sweden